Dermatology
| Psoriasis
Dermatology
Psoriasis

Bimekizumab for the treatment of moderate to severe plaque psoriasis with scalp, nail and palmoplantar involvement through 52 weeks: post-hoc analysis from the BE VIVID phase 3 trial

book_2 Source: EADV Virtual - Poster session
calendar_today Published on Medfyle: November 2020
headphones 3 min

This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.

Key messages

  • Bimekizumab is a monoclonal IgG1 antibody that inhibits IL-17F and IL-17A.
  • Post hoc analysis of subsets of patients with scalp, nail or palmoplantar psoriasis in the BE VIVID trial showed high levels of efficacy in these difficult to treat areas.
  • At Week 16, more patients achieved a scalp PGA of 0 with bimekizumab than ustekinumab or placebo.
  • Initial responses were maintained over 52 weeks in scalp and palmoplantar disease.
Presenting Author
Read more arrow_downward Hide arrow_upward

Kim A. Papp, MD
Probity Medical Research and K Papp Clinical Research, Waterloo. Ontario, Canada


Feedback